

The new European regulation on Health Technology Assessment: what changes for Advanced Therapy Medicinal Products?

Blanka Bartos, Joséphine Juët, Florence Taboulet, Aurélie Mahalatchimy

▶ To cite this version:

Blanka Bartos, Joséphine Juët, Florence Taboulet, Aurélie Mahalatchimy. The new European regulation on Health Technology Assessment: what changes for Advanced Therapy Medicinal Products?. European Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom. halshs-03901269

HAL Id: halshs-03901269 https://shs.hal.science/halshs-03901269

Submitted on 15 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.























The new European regulation on Health Technology Assessment: what changes for Advanced Therapy Medicinal Products?

Blanka Bartos¹, Joséphine Juët², Florence Taboulet³, Aurélie Mahalatchimy⁴

¹PhD Student in law, CREDIMI, Univ. of Burgundy, Dijon, 27877, France, ²Student in Pharmaceutical Sciences, Univ. of Paul Sabatier-Toulouse, 31062, France., ³Professor in Pharmaceutical Law and Health Economics, CERPOP (Center for Epidemiology and Research in POPulation health), UMR 1295 Inserm, Univ. of Paul Sabatier- Toulouse, 31062, France., ⁴ Permanent Researcher in law at the French National Centre for Scientific Research (CNRS), Faculty of Law, UMR 7318 International, Comparative and European law (DICE) CERIC, CNRS, Aix Marseille Univ., Toulon Univ. Pau & Pays de l'Adour Univ., Aix-en-Provence, 13628, France Acknowledgement: This work has been supported by ANR-funded I-BioLex project (ANR-20-CE26-0007-01, coord. A. Mahalatchimy).

Health Technology Assessment (HTA)?


"A multidisciplinary process that summarises information about the medical, patient and social aspects and the economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased and robust manner." Article 2.5) EU Regulation 2021/2282

> **Evidence-based process enabling relative effectiveness** assessment of new/ existing technologies

Health technology?

"A medicinal product, a medical device or medical and surgical procedures as well as measures for disease prevention, diagnosis or treatment used in healthcare."


Article 3.I) Directive 2011/24/EU



ATMPs are included

FUTURE (from 2025) **PAST** PRESENT (2022)

- Independent assessments from national HTA bodies
- EUnetHTA (2006-2021): joint action, voluntary cooperation



- Redundancy of the evaluation process in the EU
- Misallocation of resources
- Inequitable access to new technologies

Rolling implementation plan: preparatory phase

- Setting up the Coordination Group and the Stakeholder Network
- Drafting implementing & delegated acts, and guidance documents
- 2021-23: New EunetHTA (2021)
- States 2023-25: Member remain responsible for drawing conclusions on added value for their health system and taking decisions on pricing & reimbursement. They can give multinational additional or simultaneous national scientific advice on a voluntary basis.

Application of Joint Clinical Assessments:

- 2025: ATMPs, cancer drugs
- 2028: orphan drugs
- 2030: all medicines covered by Regulation scope

New HTA process:

- New Coordination Group managing HTA process
- Secretariat provided by the European Commission
- National bodies providing expert views on HTA
- Exchange of information with stakeholder network



- Increased quality of joint work
- Better allocation of resources: reduced expenses for national bodies and the EU
- Improved accessibility to ATMPs in the EU

Clinical and non-clinical assessments

Joint Clinical Assessments

To be considered for any HTA at Member States level

Description Collection and analysis of clinical evidence about a health technology to determine its therapeutic value compared to other technologies already available or not.

Quality, common source for States to determine pricing and reimbursement of health technology: ATMPs***

Voluntary Cooperation to exchange information, e.g., on non-clinical assessments

Description

Goal

Goal

Allowing States to exchange information on non-clinical areas, for Going beyond the clinical scope: ATMPs+++ examples on organizational, ethical, legal, and economic matters, or on health technologies other than medicines and medical devices

Support to industry Complementary tools

Joint Scientific Consultations Description

No legal effects on Member States

Early exchanges between industry and the Coordination Group.

appropriate evidence: ATMPs***

Goal

Advising on clinical studies designs to generate

Identification of Emerging Technologies (ATMPs)

Description

Goal

Coordination Group's Initiative

Reports on new technologies with potentially significant impact on patients, public health and healthcare systems.

Anticipating issues to improve patient access: ATMPs⁺⁺⁺

Remaining challenges:

- Building EU processes from national HTA experiences and feedback from experts
- Training more external expert / organisations on HTA in general, and on EU procedure(s)
- Organising HTA registries, raising awareness, collecting experiences
- Identifying / involving clinicians or patients (organisations' membership list, social networks, European Reference Networks, clinics in Pubmed...)



